Introduction
Bone marrow transplantation is increasingly used to treat hematologic, neoplastic, and immune disorders (1) . Bone marrow transplantation in humans also provides a unique opportunity to study reconstitution of cellular and humoral immune responses. One of the challenges in bone marrow transplantation is to determine ways to transfer more rapidly and effectively to the recipient an immune system capable of responding to environmental pathogens. Individuals receiving bone marrow transplantation are highly susceptible to infections in the early posttransplant period (2, 3) . Most bone marrow transplant recipients, particularly those with graft versus host disease 1 . Abbreviations used in this paper: CMV, cytomegalovirus; dip, diphtheria; GVHD, graft versus host disease; IEF, isoelectric focusing; PWM, pokeweed mitogen; tet, tetanus.
There have been several detailed studies of recovery of B cell function after bone marrow transplantation in animals and humans. Although B lymphocyte numbers rapidly return to normal soon after bone marrow transplantation, serum immunoglobulin levels remain low for a prolonged period (4) (5) (6) .
Immunoglobulin levels normalize within 6-9 mo but functional antibody responses are impaired indefinitely (6) (7) (8) (9) . In addition, the function ofT lymphocytes is reported to be abnormal after bone marrow transplantation. This is reflected in altered proportions of T lymphocyte subsets where T helper/inducer phenotype cells are reduced and T cytotoxic/suppressor cells are increased. These T and B cell abnormalities are increased in individuals with GVHD (6, 10) and aftercytomegalovirus (CMV) infection (11, 12) .
We previously studied the types ofcells and their interactions involved in the human antibody response to tetanus (tet) and diphtheria (dip) toxoids (13) (14) (15) (16) (17) . Lymphocytes in the bone marrow and blood capable of producing antibody in vitro to these antigens were identified. We defined an in vivo activated B cell (lymphoblastoid B cell), which produces specific antibody to these toxoids in the absence of other cells or factors (1 1). Also identified was a mitogen-inducible B cell, which required T helper cells in order to produce an in vitro antibody response (13) . These different B cells appeared at distinct times in the bone marrow after booster immunization (17). In the present study, transplant donors were immunized with tet/dip at defined intervals prior to transplantation. The specific types of B lymphocytes transferred and the subsequent acquisition of antigen-specific humoral immune responses and memory were studied in recipients.
Methods
Immunization. Donors received a single intramuscular injection ofcombined, absorbed tet/dip toxoids (0.5 ml) containing 5.0 flocculating units oftetanus toxoid and 1.0 flocculating units ofdiphtheria toxoid (Lederle Laboratories, Pearl River, NY). Immunization of bone marrow transplantation recipients was performed in an identical fashion at specific intervals after transplant.
Bone marrow and bloodlymphocyte cultures. Bone marrow and blood samples were obtained and lymphocytes were isolated as previously described (17) . Cultures were established with 1,500,000 lymphocytes in 1.5 ml of RPMI 1640 medium supplemented with 15% fetal calfserum, glutamine (6 mM), and gentamicin (0.04 mg/ml). Cells were cultured either alone, with pokeweed mitogen (PWM, Gibco Laboratories, Grand Island, NY) at a final concentration of 1:100 (vol/vol) or with cycloheximide at 50 ug/ml (Sigma Chemical Co., St. Louis, MO). Cells were incubated for 7 d at 370C in a humidified atmosphere containing 5% CO2. Cells were centrifuged and the supernatants collected and assayed for antibody and total immunoglobulin production.
Radioimmunoassays. Sera and cell culture supernatants were assayed for antitetanus (antitet) IgG and IgM, and antidiphtheria (antidip) IgG. Total IgG and IgM produced in the cultures was also measured using a solid-phase assay in microtiter plates (16) . Assays for specific antitet IgG and IgM were analogous except the plates were initially coated with purified tetanus toxoid (kindly provided by Wyeth Laboratories, Marietta, PA) at a concentration of I mg/ml. For each assay, a seven-point standard curve was constructed using a single antiserum ofpredetermined antibody content. The amount of antitet antibody in samples was calculated by comparison to this standard curve. The lower limit of this assay is 1 ng of specific antibody per ml. Although the absolute quantity of antibody may be underestimated by this technique (14) , relative proportions of antibody can be accurately determined in that we used a single standard throughout. Normal individuals who have not been booster immunized with tet/dip within 6 mo show a fourfold rise in antibody titer or achieve a level > 18 sg/ml of IgG antitet and 6 ug/ml IgG antidip (18) . Antidip toxoid antibodies were measured in an analogous fashion by an enzymelinked immunoassay substituting alkaline phosphatase-conjugated antihuman antibody for the iodinated anti-human antibody. The coefficient of variation in these specific antibody assays was <10%.
PWM-induced antibody synthesis was calculated by subtracting the amount detected in cultures without mitogen from the amount present in the mitogen containing cultures. The amount of antibody measured in cycloheximide-treated cultures was subtracted from the other cultures as background. Data are expressed as nanograms of antibody per 1.5 ml of culture or micrograms of antibody per milliliter of serum.
Spectrotypic analysis ofantidiphtheria fragment A antibody response.
Fragment A was obtained from diphtheria toxin by proteolytic nicking and gel filtration as described (18, 19) . Purity of fiagment A was confirmed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis.
Agarose isoelectric focusing (IEF) was performed as described (20) with the following modifications. The gel matrix was prepared by heating a 10% sorbitol-0.8% agarose mixture to near boiling. Bio-Rad ampholines (Bio-Rad Laboratories, Richmond, CA), 3.5-10, were added to a final concentration of 0.5%. The gel mixture was poured onto the hydrophobic side of GelBond film (FMC Co., Marine Colloids Div., Bioproducts, Rockland, ME). After cooling and overnight incubation at 4VC in a humidified chamber, the gel was blotted to remove excess water. Sera (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Aul) were loaded onto sample applicators and focusing was performed at 4°C. After completion of the run, the pH of the gel was determined and the gel immediately immersed in 37°C saturated sodium sulfate solution. Thereafter, the gels were incubated with '25l-fragment A for 1 hour (2,000-3,000 cpm/ng at I pig/ml in 10%6Y bovine serum albumin-phosphate-buffered saline, pH 7.6). After extensive washing and subsequent drying, the gels were fixed and autoradiographed.
Results
Bone marrow transplantation donors and recipients. Nine donor/ recipient pairs were enrolled in the study; seven pairs were evaluable. Clinical features are summarized in Table I with cyclosporine administered as a 5 mg/kg intravenous loading dose followed by 2-3 mg/kg/d by continuous intravenous infusion for 21 d, the dose being adjusted to maintain trough levels of -150 ng/ml. Oral cyclosporine (3 mg/kg) was given every 12 h from day 21 through 90. Patients with grade 2 or greater GVHD received high-dose corticosteroids which were slowly tapered as tolerated to control symptoms. Clinical details are summarized in Table I . In all patients, complete engraftment was documented by cytogenetic analysis and studies of polymorphisms of red blood cells and lymphocyte antigens and isoenzymes.
Adoptive transfer ofIgG antitetanus and diphtheria toxoid responses. Prior to booster immunization, none ofthe recipients tested had circulating cells capable of producing a significant in vitro specific IgG antitet (Table II) or antidip (Table III) antibody response. One donor (no. 6) had cells that spontaneously produced an IgG antibody response to dip; none showed a PWM response to either antigen. The levels of 1-2 ng/culture observed in some PWM cultures are minimal as PWM-induced cultures from responsive cells produce between 5 and 1,000 ng ofantitet and between 5 and 250 ng of antidip per 1.5 ml culture. The lack of response in the donors reflects no recent booster immunization with tet/dip toxoids (13) .
Donors then received a booster tet/dip immunization and their bone marrow was tested 6-7 d later at the time of transplantation. In every instance, the transplanted bone marrow was found to contain B cells spontaneously producing IgG to tet and dip toxoids (Tables II and III ). All donors subsequently dem- ence in the human response to dip versus tet toxoids as employed. We have observed this discrepancy in previous studies (21) .
There was no correlation between the donors' preimmunization antitet level and the magnitude of the increase in IgG antitet observed in the recipient. Similarly, the recipients' posttransplant increase in serum IgG antitet was unrelated to the absolute level of spontaneous IgG antitet cells detected in the transplanted bone marrow. It was also unrelated to the increase in IgG antitet detected in the donor's serum at the time oftransplantation.
One possible explanation for the rise in specific antibody in the recipients is as a result of antibody passively transferred via blood component transfusions. The blood products received by the patients during the time period of study are tabulated in Table IV . This is informative in a number of cases. Recipient 4 did not receive any blood products between days 11 and 18 while there was a marked rise in tet antibody. Recipient 1 received only a single-donor plateletpheresis transfusion between days -6 and 14 and had a large rise in antibody; between days 14 and 29 he received large quantities ofblood components with little change in tet antibody. Similarly in recipient 5, the marked rise in antibody seen before day 13 was associated with administration of few blood product transfusions. In recipient 3, there was a marked rise in antitet and antidip between days 5 and 12 when only 1 unit of packed red blood cells was given.
Sera were obtained from three similar transplant recipients who received a transplant from donors who had not been specifically immunized before transplantation. As with the immunized pairs, these donors had not received a tet/dip booster in the preceding 6 mo. In the month after transplant, these recipients showed no rise in serum antitetanus IgG > 1.5-fold. The maximum quantitative increase in antitet antibody posttransplant was 10.6 Ag/ml (5.6-6.3 ,gg/ml, 60.1-51.7 ,gg/ml, and 21.4-32.0 ,ug/ml).
Response to reimmunization in bone marrow transplantation recipients. Three transplant recipients underwent a single booster immunization with tet/dip toxoids 64-154 days posttransplant (Table V) . 7-8 d later, antitet lymphoblastoid cells were detected in the blood of these patients, and there was a subsequent rise in serum antitet levels within 28 d ofimmunization. In contrast, B cells spontaneously producing substantial IgG antidip were detected in only one individual (no. 7), and this recipient alone went on to produce a serum IgG antidip in response to the immunization. Both recipients 5 and 7 had low but detectable levels of PWM-inducible antibody responses, particularly to dip; these cells were detected prior to immunization and likely represented the PWM-inducible cells that developed after the initial immunization ofthat immune system (in the donor) pretransplant (13) . The presence of these mitogen-reactive cells, however, did not correlate with the subsequent development of antibody to tet or dip after recipient immunization.
Three bone marrow transplant recipients, whose donors had not been specifically immunized, were given a tet/dip immunization at days 88, 113, and 715, respectively, after transplantation. Two had acute myelogenous leukemia and one had lymphocytic lymphoma, all three received standard conditioning and maintenance, and none hadcytomegalovirus infection. The recipients, who were 88 and 1 antitet cell response at day 7 and her antitet IgG rose from 6.3 to 12.5 ,ug/ml. No antidip response was seen in any of these recipients.
IgM antitetanus antibody response. The IgM antitet antibody response was studied in six donor/recipient pairs (Table VI) . Prior to booster immunization, five of six donors had PWMreactive antitet IgM-reactive cells in the blood (17). Cells spontaneously synthesizing IgM antitet were not found in the blood in this or any prior study. After immunization, transplanted bone marrow cells from five of the donors demonstrated cells spontaneously producing antitet IgM. An IgM antitet serum response of twofold or greater was observed in these five donors; however, the increases were low with a maximum rise of 3.1-fold. In contrast, only one recipient showed an increase of serum We have previously shown that analytical IEF of sera from normal persons who had been booster immunized with dip toxoid is capable of detecting discrete clones of antibodies. This is especially true when only the fragment A portion of dip toxin is employed as the developing antigen. Sample anti-fragment A antibody spectrotype patterns from 14 immunized normals are shown in Fig. 1 . The majority of individuals show restriction to one or two antibody clones with each clone being characterized by a series of three to five closely spaced bands.
In three donor/recipient pairs, the clonotype pattern seen in the recipient paralleled that seen in the donor. In donor/recipient pair 1, similar spectrotypes were observed after immunization and transplantation. Prior to immunization, neither donor nor recipient serum contained detectable anti-fragment A antibodies (Fig. 2, lanes C and D) . After immunization, the donor produced a very polyclonal anti-fragment A antibody response (Fig. 2 , lane A) and this same pattern was seen in the recipient (Fig. 2,  lane B) . While the polyclonality of this response makes identification of individual clones difficult, there was clear pattern similarity. Additionally, both donor and recipient demonstrated the presence of anti-fragment A antibodies in the acidic portion of the gel. This is an unusual finding, having been observed in only 5% of a large number of donors (20) . In donor/recipient pair 5, the donor also made a heterogeneous response to fiagment A and this was transferred to the recipient (Fig. 3) . Unlike donor/ recipient pair 1, there was a well-defined spectrotype clone (near pI 7.5) that was transferred to the recipient and this spectrotype persisted. (Fig. 4 A) . For 32 d after transplantation, the recipient failed to show a resolvable pattern (Fig. 4 B) (Fig. 4 B) where increased amounts of serum were added to fully display the patterns.
Discussion
We previously studied the in vitro function and the sequence of appearance of spontaneous and mitogen-reactive antibodyproducing B cell subsets in the blood and bone marrow after booster immunization with tet/dip toxoids (17). Using the dif- They were able to accomplish this with T cell-depleted marrow. Of note, the recipients' antibody levels were equivalent to those in normals undergoing booster immunization. In addition, the responses were detectable as early as 5 d and were generally maximum between 2 and 4 wk posttransplantation (11-34 d after the donors were booster immunized). Thus antibody responses were often detected before complete hematopoietic engraftment was evident. These serum antibody responses could not be explained by passive transfer associated with blood products. To affect a rise of 100 ,gg ofIgG antitet, 2 U ofwhole blood would each have to contain 1 g ofantibody: 5-10 times the level ofantibody seen in boosted individuals. Furthermore, some patients (i.e., nos. 1, 3, 4, 5, and 6), had a clear rise in antibody titers when no or little blood products were given.
Analysis by IEF of spectrotypes of antidip fragment A in several donor/recipient pairs revealed the development of identical spectrotypic patterns ofantibody responses from the donor B cells in both the donor and recipient. Thus, while Wahren et al. (23) suggested the persistence of recipient antiviral antibody production for several months posttransplantation, we demonstrated that the antibody responses that we observed were the results from the adoptive transfer of donor-specific immune re-Saxon et al. Thus, by transfer of B cells spontaneously synthesizing specific antibody (lymphoblastoid B cells), we were able to transfer specific immunologic memory in addition to an active adoptive antibody response. These findings are in accord with extensive studies in murine models where it has been known for many years that specific antibody can be transferred with spleen and bone marrow and that donor immunization influences the reconstitution of specific humoral immunity in the recipient (25) (26) (27) (28) . Since PWM-reactive antigen-specific B cells were not present in the donor bone marrow (Table II) or at the time of reimmunization (Table V) , it is unlikely that such cells are directly involved in the memory response. It is possible that PWM-reactive cells play a role in the development of B cell memory; however, they must appear at times other than those we studied. Two cases ofpossible inadvertent transfer ofspecific IgE memory responses by marrow transplantation have been reported, however the data were not definitive (29, 30) .
There is a prolonged period of severe cellular and humoral immunodeficiency after bone marrow transplantation. Although the number of B cells in the blood usually normalizes by the third month, IgG and IgM levels do not return to normal until 4-6 mo posttransplant. IgA levels remain depressed for a year or more. Qualitative function of humoral immunity, particularly to T-dependent antigens, remains depressed for prolonged periods. Witherspoon and co-workers reported that responses to phage 0174 are depressed for more than 3-4 mo (7, 8 (11, (32) (33) (34) (35) (36) (37) (38) (39) . Similar problems exist with respect to recovery of T cell-mediated immunity (20, 24, 31 
